DXCM Long Call Strategy
DXCM (DexCom, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators.
DXCM (DexCom, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $22.60B, a trailing P/E of 24.24, a beta of 1.40 versus the broader market, a 52-week range of 54.11-89.98, average daily share volume of 4.5M, a public-listing history dating back to 2005, approximately 10K full-time employees. These structural characteristics shape how DXCM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.40 indicates DXCM has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on DXCM?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current DXCM snapshot
As of May 15, 2026, spot at $61.55, ATM IV 40.94%, IV rank 25.17%, expected move 11.74%. The long call on DXCM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this long call structure on DXCM specifically: DXCM IV at 40.94% is on the cheap side of its 1-year range, which favors premium-buying structures like a DXCM long call, with a market-implied 1-standard-deviation move of approximately 11.74% (roughly $7.22 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DXCM expiries trade a higher absolute premium for lower per-day decay. Position sizing on DXCM should anchor to the underlying notional of $61.55 per share and to the trader's directional view on DXCM stock.
DXCM long call setup
The DXCM long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DXCM near $61.55, the first option leg uses a $62.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DXCM chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DXCM shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $62.00 | $2.53 |
DXCM long call risk and reward
- Net Premium / Debit
- -$252.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$252.50
- Breakeven(s)
- $64.53
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
DXCM long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on DXCM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$252.50 |
| $13.62 | -77.9% | -$252.50 |
| $27.23 | -55.8% | -$252.50 |
| $40.83 | -33.7% | -$252.50 |
| $54.44 | -11.5% | -$252.50 |
| $68.05 | +10.6% | +$352.47 |
| $81.66 | +32.7% | +$1,713.26 |
| $95.27 | +54.8% | +$3,074.06 |
| $108.87 | +76.9% | +$4,434.85 |
| $122.48 | +99.0% | +$5,795.65 |
When traders use long call on DXCM
Long calls on DXCM express a bullish thesis with defined risk; traders use them ahead of DXCM catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
DXCM thesis for this long call
The market-implied 1-standard-deviation range for DXCM extends from approximately $54.33 on the downside to $68.77 on the upside. A DXCM long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current DXCM IV rank near 25.17% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DXCM at 40.94%. As a Healthcare name, DXCM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DXCM-specific events.
DXCM long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DXCM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DXCM alongside the broader basket even when DXCM-specific fundamentals are unchanged. Long-premium structures like a long call on DXCM are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current DXCM chain quotes before placing a trade.
Frequently asked questions
- What is a long call on DXCM?
- A long call on DXCM is the long call strategy applied to DXCM (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With DXCM stock trading near $61.55, the strikes shown on this page are snapped to the nearest listed DXCM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are DXCM long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the DXCM long call priced from the end-of-day chain at a 30-day expiry (ATM IV 40.94%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$252.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a DXCM long call?
- The breakeven for the DXCM long call priced on this page is roughly $64.53 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DXCM market-implied 1-standard-deviation expected move is approximately 11.74%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on DXCM?
- Long calls on DXCM express a bullish thesis with defined risk; traders use them ahead of DXCM catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current DXCM implied volatility affect this long call?
- DXCM ATM IV is at 40.94% with IV rank near 25.17%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.